lilly glp-1 New clinical trial data from Eli shows its daily weight loss pill can reduce body weight by up to 11% over time. ABC News medical correspondent Dr. Darien Sutton joins Linsey Davis to Lilly says its experimental GLP-1

doi: 10.1002/j.1939-4640.1995.tb00561.x, 220

This interaction could potentially limit the cellular absorption of OxLDL, which is reputed to contribute to atherogenic processes

Early research finds some possible actions BPC-157 might have, including: Angiogenesis (new blood vessel growth) Collagen synthesis and fibroblast activity (tissue repair) Nitric oxide regulation (vasodilation and blood flow) Even if BPC-157 caused these effects in humans, we still dont know whether the net effect would be good

[26] Another randomized, double-blinded, placebo-controlled trial was conducted in 54 adults which administered oral glutathione for six months, either in a dose of 250 mg or 1000 mg per day

This hinted at what higher doses might do for obesity (discussed soon)

One potential mechanism could be increased prevalence of NAION risk factors in patients starting GLP-1RA or that sudden and rapid decline in blood glucose could increase the risk of diabetic papillopathy or worsened DR